Infusion Center Economics Model
A planning-level model for infusion chair economics. For a decision involving real capital, request a full pro forma that includes payer mix, drug acquisition cost, staffing and 340B eligibility.
- Browser tool
- Planning-level estimate only
- Nothing stored
Chair count and utilization set the ceiling on volume.
Chair count and utilization set the ceiling on volume. Payer mix, drug cost, staffing and site of care determine what that volume is worth; this model gives a directional first read before a full pro forma.
Enter your own assumptions.
A directional estimate only — see the disclaimer below the results.
Estimated monthly infusions
252
Estimated monthly gross revenue
$163,592
A directional planning estimate only — it does not include payer mix, drug acquisition cost, 340B overlay, staffing cost or site-of-care effects. A full pro forma models all of those together against your actual volumes.
The variable many infusion pro formas leave out.
In oncology and specialty infusion, drug cost can outweigh facility and staffing cost. Whether a location is a registered, 340B-eligible hospital outpatient site can materially change the economics.
Before moving infusion services, model chair utilization, payer mix, site-neutral reimbursement and 340B eligibility together.
Using this planning estimate
How do you calculate infusion chair capacity?
Multiply the number of chairs by infusions per chair per day, utilization and operating days. For example, 8 chairs × 2.2 infusions × 65% utilization × 22 days is about 252 infusions per month.
What is a good infusion chair utilization rate?
It depends on treatment mix, scheduling and staffing. Many centers track utilization by chair hour rather than visits because treatment lengths vary widely.
Can a freestanding infusion center use 340B drugs?
Only if it is a registered site of an eligible covered entity. Confirm the site’s eligibility and registration with qualified 340B and legal advisors.